Insulet announced the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Insulet plans to commercialize Omnipod GO in the United States in 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- Medtronic approval only ‘incremental positive,’ says Piper Sandler
- Medtronic 780G system approval an ‘incremental positive,’ says Morgan Stanley
- Tandem Diabetes down 5% after FDA approves Medtronic’s MiniMed 780G
- Insulet price target raised to $342 from $300 at Stifel
- Piper wonders if Medtronic’s 780G will be delayed further by FDA inspections
